EYP651/Transporter substrate

Phase 1Small molecule

EYP651/Transporter substrate is one of 7 small molecule programs targeting Drug Interactions. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Drug InteractionsRecruiting

Drug InteractionsPhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Drug Interactions

#DrugCompanyPhaseTrials

Ofev

Boehringer Ingelheim

Phase 1

4 2

Esbriet

LLegacy Health System

Phase 1

3 3

DWP16001

Daewoong Pharmaceutical Co. LTD.

Phase 1

1 4

Onglyza

AstraZeneca

Preclinical

1 5

Drug Cocktail

Eli Lilly

Phase 1

1 6

EYP651/Transporter substrate

EEnyo Pharma

Phase 1

1 7

Taladegib

EEndeavor Biomedicines, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug Interactions1 trial

Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt and Evaluation of Potential Drug-Drug Interactions

Recruiting·EEnyo Pharma·Phase 1·NCT07251153·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EYP651/Transporter substrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EYP651/Transporter substrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EYP651/Transporter substrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enyo Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEnyo Pharma

EYP651/Transporter substrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Drug Interactions1 trial

References

Drug Info

Quick Facts

Related News